

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Figure 1: Anti-Flt-1 Ribozyme: *ANGIOZYME*



Inhibition of LLC-HM Primary Tumor Growth Following Systemic ANGIOZYME




Figure 2

ANGIOZYME Inhibition of Lung Metastases (LLC-HM Model)





Figure 3

Effect of ANGIOZYME on Liver Metastases in a Colorectal Cancer Model



Note: > 100 metastases are indicated as 101.

Figure 4

Figure 5: Plasma concentration profile of ANGIOZYME after a single subcutaneous dose of 10, 30, 100 or 300 mg/m²




Figure 6: Examples of Nuclease Stable Ribozyme Motifs




Figure 7: Stabilized Zinzyme Ribozyme Motif





Figure 8: DNAzyme Motif



Legend
Y = U or C
R = A or G

Figure 9: Soluble VEGFR1 Reduction






Figure 10: Mouse Model of Proliferative Retinopathy



Note: Peak VEGF levels noted 12 hr after exposure to room air

**Figure 11: RPI.4731 Reduces Hypoxia-Induced Retinal
Neovascularization in Neonatal Mice**



**Results: ~40% decrease in retinal neovascularization
following two intraocular injections of RPI.4731**

SEQ ID NO: 5978